IL2 and myocardial ischemia: A randomized, double-blind, dose-escalation, placebo-controlled, phase I/IIa clinical trial is ongoing to assess the tolerability and safety of IL-2 in patients with ischemic heart disease (IHD) and ACS (Zhao et al., 2018b).